Do not stop treatment abruptly & taper dose upon discontinuation. Consider increasing therapy w/ corticosteroids or antibiotic treatment if infection is present. Not intended for regular prophylactic use eg, before exercise. Regularly assess patients w/ asthma. Do not initiate treatment during an exacerbation or if they have significantly worsening or acutely deteriorating asthma. COPD patients w/ pre-bronchodilator FEV1 >50% predicted normal & w/ a post-bronchodilator FEV1 <70% predicted normal. Discontinue treatment if paradoxical bronchospasms occur & assess patient; institute alternative therapy if necessary. Systemic effects may occur especially in long periods. Visual disturbance. Consider potential effects on bone density particularly in patients on high doses for prolonged periods that have co-existing risk factors for osteoporosis. Risk of impaired adrenal reserve in patients transferring to a budesonide/formoterol fumarate fixed-dose combination therapy; regularly monitor hypothalamic pituitary adrenocortical axis. Consider additional systemic corticosteroid cover during periods of stress eg, severe infections or elective surgery in prolonged treatment. Oral infections. Increased risk of pneumonia in patients w/ COPD. Avoid concomitant use w/ itraconazole, ritonavir or other potent CYP3A4 inhibitors. Patients w/ thyrotoxicosis, phaeochromocytoma, DM, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe HTN, aneurysm or other severe CV disorders eg, ischaemic heart disease, tachyarrhythmias or severe heart failure; prolonged QTc-interval. Re-evaluate treatment in patients w/ active or quiescent pulmonary TB, fungal & viral infections in the airways. Consider additional blood glucose controls in diabetic patients. Concomitant treatment w/ drugs that can induce hypokalaemia or potentiate a hypokalaemic effect eg, xanthine-derivatives, steroids & diuretics. Unstable asthma w/ variable use of rescue bronchodilators in acute severe asthma; monitor serum K. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Pregnancy & lactaction. Regularly monitor height in childn receiving prolonged treatment.